• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

Remdesivir in adults with severe COVID-19

byAlex ChanandRavi Shah, MD MBA
May 18, 2020
in Infectious Disease, Pulmonology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

RELATED REPORTS

#VisualAbstract: Molnupiravir improves outcomes in non-hospitalized COVID-19 patients

Risk of myocarditis or pericarditis after COVID-19 mRNA vaccination is highest among younger males

Vaccination boosted immunity acquired from previous SARS-CoV-2 infection

1. Adults with severe COVID-19 treated with remdesivir had numerically faster time to clinical improvement compared to controls, but the difference was not statistically significant

Evidence Rating: 2 (Good)

Months into declaration of COVID-19 as a pandemic, there still remains to be an antiviral therapy of proven effectiveness in treating the disease. Remdesivir has been an agent receiving great media attention, as it has shown significant anti-viral activity against coronaviruses in vitro, including SARS-CoV-2, and isolated case studies have reported a benefit in using the drug for affected patients. To formally address its clinical efficacy, researchers recruited 237 patients with laboratory confirmed pneumonia from SARS-CoV-2 in a randomized, double-blind, placebo-controlled multicenter trial, randomly assigning patients in a 2:1 ratio to either receive remdesivir (200mg on day 1 IV followed by 100mg for 9 days following) or a placebo infusion. The primary endpoint of interest was clinical improvement up to day 28, defined as time from randomization to point of a decline in two levels on a six-point ordinal scale. Patients assigned to the treatment group had a numerically faster time to clinical improvement compared to the placebo group  (median 18·0 days [IQR 12·0–28·0] vs 23·0 days [15·0–28·0]; HR 1·52 [0·95–2·43]), but results were not statistically significant. Likewise, rates of clinical improvement at days 14 and 28 were higher for the treatment group than placebo, but again, not statistically significant. Similar mortality rates were observed, and no significant differences were observed between the two groups in length of oxygen support, hospital stay, days from randomization to discharge, or time to clearance of virus. The treatment regimen was well tolerated by the remdesivir group, with similar rates of adverse events compared to the placebo recipients. Overall, while minute differences in clinical course were observed between the two groups, no significant clinical or antiviral effects were found at the treatment dose in this study. Future investigations may choose to use larger sample sizes or initiate treatment earlier in the disease course to continue informing the collective understanding of potential antiviral therapies for COVID-19.

Click to read the study in Lancet

Image: PD

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: CoronavirusremdesivirSARS-CoV-2
Previous Post

Renin-angiotensin-aldosterone system inhibitors do not affect COVID-19 risk

Next Post

2 Minute Medicine Rewind May 18, 2020

RelatedReports

#VisualAbstract: Molnupiravir improves outcomes in non-hospitalized COVID-19 patients
StudyGraphics

#VisualAbstract: Molnupiravir improves outcomes in non-hospitalized COVID-19 patients

June 30, 2022
Atrial fibrillation-specific management increases days alive and out of hospital
Cardiology

Risk of myocarditis or pericarditis after COVID-19 mRNA vaccination is highest among younger males

June 22, 2022
Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children
Chronic Disease

Vaccination boosted immunity acquired from previous SARS-CoV-2 infection

May 13, 2022
Novel coronavirus identified from patients with pneumonia in Wuhan, China
Chronic Disease

Single-dose Ad26.COV2.S vaccine provides moderate protection against Covid-19 related outcomes

May 13, 2022
Next Post
Thrombophilia-associated stillbirth risk appears limited to factor V Leiden

2 Minute Medicine Rewind May 18, 2020

Vitamin D supplementation amongst post-menopausal women did not improve functional outcomes

Direct oral anticoagulants associated with lower risk of osteoporotic fracture versus warfarin

Improved glycemic control in type 1 diabetics on very low-carbohydrate diets

Diets rich in fruits and vegetables may protect heart health

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Relugolix combination therapy is efficacious for endometriosis-associated pain
  • Age-based products and longer interdose intervals may reduce the risk of cardiac disease following COVID-19 mRNA vaccination
  • OPTN and UNOS update policy regarding hepatocellular carcinoma [Classics Series]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.